Mukka Proteins Limited has informed the Exchange regarding Board meeting held on February 12, 2026.
MUKKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 1.4 pts less than its Food Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mukka Proteins reported consolidated Q3 FY26 revenue from operations of Rs. 6,534.97 million, more than doubling from Rs. 3,031.52 million in Q3 FY25. For the nine months ended Dec 31, 2025, consolidated revenue rose about 71% to Rs. 10,688.52 million. However, profitability was under pressure: Q3 consolidated profit after tax was largely flat at Rs. 272.53 million, and standalone PAT actually fell to Rs. 187.59 million from Rs. 251.02 million a year ago, reflecting margin compression from higher raw material and finance costs. The Board approved making Ento Proteins and Haris Marine Products wholly-owned subsidiaries through small additional share purchases, and also disclosed a Rs. 76.70 million customs duty demand as a contingent liability. Auditor Shah & Taparia issued an unmodified (clean) review opinion on both standalone and consolidated results.
Strong topline growth on the back of recent acquisitions is positive, but the sharp drop in margins and weaker standalone profit may weigh on the stock in the short term. The subsidiary consolidation is largely administrative, while the customs demand and continued finance cost growth remain watchpoints for shareholders.